MOverview
MiniMed develops insulin delivery and automated insulin delivery systems, plus related sensors, pens, and software. Its products couple glucose sensors with pumps or smart pens to automatically adjust insulin or simplify dosing. It differentiates itself with an integrated ecosystem of devices and software and a large share of recurring revenue from sensors, consumables, software and services across more than 80 countries. Its goal is to be a leading global provider of insulin delivery and glucose monitoring solutions that help people with diabetes achieve better glycemic control.
Work here?Claim your company
About MiniMed
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Los Angeles, CA
Founded
1983
Get referred to MiniMed
See people who can refer or advise you
Simplify's take
What believers are saying
- November 2026 CMO hire David Segal strengthens clinical credibility and digital-health execution.
- March 2026 CE Mark with Abbott's Instinct expands 780G and Go European access.
- Fit patch pump submitted early in August 2026, targeting U.S. launch in 2027.
What critics are saying
- FDA recalls for 780G and loaner pumps hit July 2026, exposing quality-control failures.
- Blackstone royalties on Flex and Fit take up to $162 million per product.
- MiniMed still faces U.S. and Canada product-liability suits; a 780G failure becomes existential.
What makes MiniMed unique
- March 2026 Flex and Go launches unite pumps, sensors, software, and service.
- MiniMed sells in 80 countries, with roughly 70% of sales outside America.
- October 2026 independence lets Que Dallara tailor capital, product, and commercial decisions.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$560M
Above
Industry Average
Funded Over
2 Rounds
Stock Price
Company News
MiniMed (Nasdaq: MMED), a diabetes technology company, has appointed David Segal as chief medical officer, effective immediately. Dr. Segal succeeds Robert Vigersky, who becomes chief medical officer emeritus before retiring at the end of 2027. Dr. Vigersky joined the Medtronic Diabetes business in 2015 and has held the role since 2019. Dr. Segal has more than 20 years of experience in diabetes care and digital health. He most recently served as medical director of innovation and remote monitoring care at Parkview Health's Mirro Center for Research and Innovation. He also founded South Africa's largest diabetes and endocrinology practice and co-founded the tele-coaching company Guidepost. "His experience and perspective will be invaluable," said chief executive officer Que Dallara.
MiniMed appoints Dr. David Segal as Chief Medical Officer. MWN-AI** Summary. MiniMed, a prominent player in diabetes technology, announced the appointment of Dr. David Segal as its new Chief Medical Officer on November 3, 2026. Dr. Segal succeeds Dr. Robert Vigersky, who will transition to the role of Chief Medical Officer Emeritus before retiring at the end of 2027. With over two decades of experience in diabetes care and a focus on integrating technology and data to enhance patient outcomes, Dr. Segal's expertise is anticipated to significantly contribute to the company's continuing innovation. Que Dallara, CEO of MiniMed, expressed enthusiasm about Dr. Segal joining the team, highlighting his clinical expertise and vision for leveraging technology in diabetes care. Dr. Segal's previous role as Medical Director of Innovation and Remote Monitoring Care at Parkview Health, coupled with his experience in establishing South Africa's largest diabetes and endocrinology practice, positions him well to lead MiniMed's clinical strategies. Additionally, he co-founded Guidepost, a digital health entity offering diabetes tele-coaching services. Dr. Segal emphasized his passion for making diabetes management proactive, personalized, and accessible, expressing excitement about contributing to MiniMed's technology development aimed at improving the quality of life for individuals living with diabetes. He holds a medical degree from the University of the Witwatersrand and has completed his pediatric residency at Cleveland Clinic, alongside an endocrinology fellowship at Riley Children's Hospital. As MiniMed continues to innovate in insulin delivery and related technologies, Dr. Vigersky's legacy of advancing clinical strategy since joining the company in 2015 provides a strong foundation for Dr. Segal's leadership in the years ahead. MWN-AI** Analysis. MiniMed's recent appointment of Dr. David Segal as Chief Medical Officer is a strategic move that investors should closely monitor, particularly in the context of the diabetes technology market. Dr. Segal's extensive background in diabetes care, digital health, and healthcare innovation positions him as a key figure to drive MiniMed's future growth initiatives. With over two decades of experience, Dr. Segal has successfully blended technology with patient care, a vital aspect of any modern healthcare company. His previous roles, notably at Parkview Health and in establishing large-scale diabetes practices, underscore his capability to spearhead innovations that can enhance patient outcomes. This dovetails perfectly with MiniMed's mission to reduce the daily burdens of diabetes management through integrated technology. The transition from Dr. Robert Vigersky, who has laid a solid clinical groundwork, to Dr. Segal marks a pivotal moment for MiniMed. Investors should note that the leadership change often brings fresh perspectives, which can invigorate product development and service offerings. As MiniMed aims to advance its innovation pipeline, Dr. Segal's focus on personalized and proactive diabetes management will be crucial in differentiating the company in a competitive landscape. Market analysts should watch for potential performance indicators such as product launches or updates that leverage Dr. Segal's expertise in digital health. Additionally, with growing awareness and investment in chronic disease management, especially diabetes, the demand for MiniMed's offerings is likely to rise. In conclusion, MiniMed's strategic leadership enhancements position it well for future growth. Investors might consider gradually accumulating shares as the company's initiatives under Dr. Segal unfold, potentially leading to stronger clinical outcomes and enhanced market position. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. November 03, 2026 09:20:00 am PR Newswire NORTHRIDGE, Calif., Nov. 3, 2026 /PRNewswire/ - MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the appointment of David Segal, M.D., as Chief Medical Officer. Dr. Segal succeeds Robert Vigersky, M.D., who will transition to the role of Chief Medical Officer Emeritus ahead of his planned retirement at the end of 2027. Dr. Segal brings more than 20 years of experience in diabetes care, digital health and healthcare innovation, with a focus on using technology and data to improve patient outcomes and expand access to care. "Dr. Segal brings deep clinical expertise and a passion for using technology to improve diabetes care," said Que Dallara, chief executive officer of MiniMed. "His experience and perspective will be invaluable as we continue delivering strong clinical outcomes with our technologies and advancing our innovation pipeline. We're excited to welcome him to MiniMed and grateful for the strong foundation Dr. Vigersky has established." Most recently, Dr. Segal served as Medical Director of Innovation and Remote Monitoring Care at Parkview Health's Mirro Center for Research and Innovation, where he also helped establish a pediatric endocrinology service. Previously, he established South Africa's largest diabetes and endocrinology practice and co-founded Guidepost, a digital health company providing diabetes tele-coaching services. "I've spent much of my career looking at how we can use technology and data to make diabetes care more proactive, personalized and accessible," said Dr. Segal. "What excites me about MiniMed is the opportunity to bring that thinking into the development of technologies that can reduce the daily burden of managing diabetes and help more people achieve better outcomes." Dr. Segal earned his medical degree from the University of the Witwatersrand in South Africa and completed his pediatric residency at Cleveland Clinic and endocrinology fellowship at Riley Children's Hospital. He was appointed Honorary Adjunct Professor at the University of the Witwatersrand in 2016. Dr. Vigersky joined the Medtronic Diabetes business in 2015 and has served as Chief Medical Officer since 2019, helping advance the company's clinical strategy. A retired U.S. Army Medical Corps colonel, he has authored more than 425 scholarly papers and abstracts focused on improving diabetes outcomes through technology. About MiniMed MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Its full-stack, integrated ecosystem, including its insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, Market Wire News has pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Its mission is to make every day a better day for people with diabetes. Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. SOURCE MiniMed FAQ**. How might Dr. David Segal's appointment as Chief Medical Officer impact MiniMed Group Inc. MMED's innovation pipeline in diabetes care technology? Dr. David Segal's appointment as Chief Medical Officer could invigorate MiniMed Group Inc.'s innovation pipeline in diabetes care technology by leveraging his expertise to accelerate research and development efforts, ultimately enhancing product offerings and boosting market competitiveness. What specific initiatives does MiniMed Group Inc. MMED plan to implement under Dr. Segal's leadership to enhance patient outcomes in diabetes management? Under Dr. Segal's leadership, MiniMed Group Inc. plans to implement advanced digital tools, personalized treatment protocols, and a focus on real-time data analytics to enhance patient outcomes in diabetes management. Given Dr. Segal's background in pediatric endocrinology, how will MiniMed Group Inc. MMED address the unique needs of younger diabetes patients? MiniMed Group Inc. MMED plans to leverage Dr. Segal's expertise in pediatric endocrinology to develop tailored diabetes management solutions that focus on the specific biological, emotional, and lifestyle needs of younger patients, enhancing their overall care. How does MiniMed Group Inc. MMED envision leveraging Dr. Segal's experience in digital health to expand access to diabetes care for underserved populations? MiniMed Group Inc. envisions leveraging Dr. Segal's digital health expertise to develop innovative solutions that enhance accessibility and affordability of diabetes care for underserved populations, ultimately aiming to improve health outcomes and reduce disparities in care. **MWN-AI FAQ is based on asking OpenAI questions about MiniMed Group Inc. (NASDAQ: MMED).
Medtronic has retired about 55 million of its own shares after the split-off of its diabetes unit, now called MiniMed. The shares came back through an oversubscribed exchange offer, which spreads future net income across fewer shares and helps earnings per share. The company has raised its dividend for 49 consecutive years, including a 1.4% rise in 2026. Another increase in 2027 would add it to the Dividend Kings, a list of 59 US stocks with 50 or more years of increases. In the quarter ended July 31, revenue rose nearly 14% to $9.8 billion, and earnings per share rose 15% to $1.45. Fiscal 2026 revenue was $36.4 billion, up 8.4%. The stock trades at about 16 times forward earnings, below peers such as Johnson & Johnson, Abbott, and Stryker.
MiniMed names post-separation board of directors, adds Walgreens executive Amy Bricker. October 16, 2026 Amy Bricker MiniMed (Nasdaq: MMED), a global diabetes technology company, has announced the composition of its board of directors following its separation from Medtronic, with Kevin E. Lofton continuing as chairman and Amy Bricker, executive vice president of enterprise pharmacy at Walgreens, joining as an independent director. Bricker's appointment, effective immediately, is part of MiniMed's planned transition away from Medtronic-designated directors as the company establishes its governance structure following its March 2026 Nasdaq listing. The eight-member board brings together executives with experience in healthcare delivery, pharmacy services, medical technology, manufacturing, finance and corporate governance. MiniMed said the board will support its priorities as an independent public company, including business growth, product innovation, operational execution and expanded access to diabetes management technologies. Que Dallara, chief executive officer of MiniMed, said the company's independence provides an opportunity to focus its operations and technology development on the needs of people living with diabetes. "As an independent public company, MiniMed has a clear mission: reduce the burden of diabetes management and make integrated technology easier to access and use," Dallara said. "That requires a Board that understands healthcare access and patient needs, and can also help us execute across technology, commercial operations, manufacturing, finance and governance." Lofton, who remains chairman, previously served as chief executive officer of CommonSpirit Health, one of the largest nonprofit healthcare systems in the United States. CommonSpirit was formed through the 2019 combination of Catholic Health Initiatives and Dignity Health. Before leading the combined organization, Lofton served for nearly two decades as CEO of Catholic Health Initiatives. He also held chief executive positions at Howard University Hospital and UAB Hospital. Lofton currently serves on the boards of Medtronic, Howard University and the Georgia State University Foundation. His previous board appointments include Gilead Sciences and Rite Aid. At MiniMed, he serves on the nominating and corporate governance committee and the compensation and talent committee. Bricker joins the board with more than 25 years of experience spanning pharmacy benefit management, retail pharmacy, consumer healthcare and government healthcare programs. At Walgreens, she oversees community and specialty pharmacy strategy and operations. Previously, Bricker served as president of Express Scripts, where she led a business generating more than $100 billion in annual revenue and serving more than 100 million covered lives. A pharmacist by training, she also served as a commissioner on the Medicare Payment Advisory Commission, contributing to discussions involving healthcare reimbursement and pharmacy-related policy. Bricker will serve on MiniMed's nominating and corporate governance committee. Her appointment adds experience in healthcare access, reimbursement and consumer-facing pharmacy operations as MiniMed works to expand the availability and adoption of its diabetes technologies. Dallara, who became MiniMed's CEO in March 2026, also serves on the board. She previously led Medtronic's diabetes business as executive vice president and president beginning in 2022, overseeing its return to growth and subsequent separation from Medtronic. Before joining Medtronic, Dallara held senior leadership positions at Honeywell, including president and CEO of Honeywell Connected Enterprise and senior vice president and chief commercial officer. Her earlier experience includes positions at TE Connectivity, Microsoft, Telstra and McKinsey & Company. She also serves on the board of Lattice Semiconductor. Glenn Eisenberg, former executive vice president and chief financial officer of Labcorp, serves as chair of MiniMed's audit committee and as a member of its nominating and corporate governance committee. Eisenberg was Labcorp's CFO from 2014 to 2024, during which the company completed approximately 100 acquisitions representing roughly $11 billion in investment. He previously held senior financial and operating positions at The Timken Company and United Dominion Industries. Eisenberg currently serves on the boards of Solventum, Lumexa Imaging and Middleby. David Endicott, chief executive officer of Alcon, brings experience leading a medical technology business through separation from a larger parent company. Endicott has served as Alcon's CEO since 2018 and joined its board in 2019. He previously served as the company's chief operating officer and helped lead its transition to independent public company status. His career also includes leadership positions at Hospira Infusion Systems and Allergan. Endicott serves on MiniMed's compensation and talent committee. Keith Grossman, former president and CEO of Nevro Corp., serves as chair of MiniMed's nominating and corporate governance committee and as a member of its audit committee. Grossman has more than 35 years of medical device industry experience and has served as CEO of four public companies. His previous leadership roles include Thoratec Corporation, which was acquired by St. Jude Medical for $3.4 billion, and Conceptus. He currently serves as vice chairman of Alcon and chairman of Outset Medical. Bob Hopkins, senior vice president and head of global strategy at Medtronic, remains on the MiniMed board. Hopkins oversees corporate strategy at Medtronic, including capital allocation and portfolio management. Before joining Medtronic in 2021, he was a managing director and senior equity research analyst at Bank of America Merrill Lynch, covering the medical technology sector. He brings more than 25 years of experience in medical technology and financial analysis. Timothy Wicks, former executive vice president and CFO of Optum, serves as chair of MiniMed's compensation and talent committee and as a member of its audit committee. Wicks spent nearly two decades with UnitedHealth Group, holding leadership responsibilities across Optum Financial, Supply Chain and OptumRx. His experience includes healthcare operations, product development, strategic partnerships and financial management. He currently serves on the boards of BrightSpring and Global Medical Response. The board's composition reflects MiniMed's effort to combine medical technology expertise with experience in healthcare delivery, reimbursement, commercial operations and public company oversight. The governance transition follows MiniMed's separation from Medtronic and its establishment as a publicly traded company in March 2026. MiniMed develops integrated diabetes management technologies, including insulin delivery systems, continuous glucose monitors, algorithms, software applications and related patient support services. The company operates in 80 countries and has more than 40 years of experience developing diabetes therapies. As an independent company, MiniMed plans to focus on connecting insulin delivery, glucose sensing, software and clinical support into a more integrated experience for patients. The updated board will oversee that strategy as MiniMed pursues growth, product development and broader access to its diabetes management systems.
Medtronic is offering shareholders an exchange of up to 80.1% of its diabetes business MiniMed for Medtronic shares, worth about $4 billion. A Barron's report on 2 October suggested the offer is losing appeal. If the swap stalls, Medtronic's share count reduction plans would be affected. The exchange is worth more than three times the $1.2 billion spent on buybacks over the past twelve months. The company has no other large share count reductions planned. Medtronic's adjusted gross margin could also be impacted, as management stated the diabetes business contributed to margin pressure in fiscal Q1 2027. The diabetes unit reported 15% growth that quarter, though this included an extra selling week. Medtronic has scheduled an Investor Day for 10-11 December. A firm closing date announced then would indicate the separation remains on schedule to close before fiscal year-end.
MiniMed is Hiring for 141 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About MiniMed
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Los Angeles, CA
Founded
1983
MiniMed is Hiring for 141 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs